Short answer
Kyverna Therapeutics Inc (KYTX) filed an 8-K current report with the SEC on July 9, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). $150.0M non-dilutive loan facility, with $25.0M already drawn and $15.0M Term A capacity remaining.
Kyverna Therapeutics Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $150.0M non-dilutive loan facility, with $25.0M already drawn and $15.0M Term A capacity remaining
- Term A availability extended through December 31, 2026, for a $187,500 upfront cash fee
- Failure to draw the remaining $15.0M triggers a 1.0% non-utilization fee on undrawn Term A commitments
- Full Term A draw conditionally extends Term B availability to September 30, 2027 and restructures Term C into two $20.0M tranches
- Minimum revenue covenants begin as early as the quarter ending June 30, 2027, depending on additional capital raised
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Kyverna Therapeutics Inc 8-K filings
Get the next KYTX 8-K as it lands
Follow KYTX for push alerts, or ask the research agent what this filing means.